OIPE 18 2001



Box/Seq.

| 79.0 m | TRANSMITTAL LET | Case No. 10466/71 | | |
|--------------------|----------------------------|-------------------------------|----------------|--|
| SBASTINO. | Filing Date | Examiner | Group Art Unit | |
| 09/902,713 | July 10, 2001 | To be assigned | 1645 | |
| Inventor(s) | | | | |
| Ashkenazi et al. | | | | |
| Title of Invention | | | | |
| SESSETED AND TOAK | ISMEMBRANE POLYPEPTIDES AI | ND AUTOL ETO A OIDO EN OODUNO | THE CARAC | |

TO THE COMMISSIONER FOR PATENTS

| Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); 2 compact discs of Sequence Listing; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and return postcard. | | | | | | | | | | | | | |
|--|--|----------------|---------------------------------------|------------------|--------------------|--------------|----------|----------------------------|--------------|--|--|--|--|
| | Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted. | | | | | | | | | | | | |
| | A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed. | | | | | | | | | | | | |
| | Petition for amonth extension of time. | | | | | | | | | | | | |
| \boxtimes | No additional fee is required. | | | | | | | | | | | | |
| | The fee has been calculated as shown below: | | | | | | | | | | | | |
| | Small Entity | | | | | | | Other Than Small Entity | | | | | |
| | Claims Remaining After Amendment | | Highest No. Previously Paid For | Present Extra | Rate | Add'I Fee | or | Rate | Add'I Fee | | | | |
| Total | | Minus | | | x \$9= | | | x \$18= | | | | | |
| Indep. | | Minus | | | x 42= | | - | x \$84= | | | | | |
| First Presentation of Multiple Dep. Claim + \$140 = | | | | | | | + \$280= | | | | | | |
| | | | | | Total add'l fee | \$ | | Total add'I fee | \$ | | | | |
| Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed. | | | | | | | | | | | | | |
| | A check in the amount of \$ to cover the filing fee is enclosed. | | | | | | | | | | | | |
| \boxtimes | The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. | | | | | | | | | | | | |
| | I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. | | | | | | | | | | | | |
| | Gregory M. Zinkl, Ph.D. Registration No. 48,492 Agent for Applicant | | | | | | | | | | | | |
| P.O. BO | O, ILLINOIS 606 | | | , | | | | | | | | | |
| express ma Commission | | 4066US, with s | yellow | | | | | | | | | | |





COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/902,713

07/10/2001

Avi Ashkenazi .

P1618P2C34

CONFIRMATION NO. 1320

FORMALITIES LETTER

OC000000007000326

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599



Date Mailed: 10/31/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- □ For Rules Interpretation, call (703) 308-4216
- □ To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202